Chronic Kidney Disease Stage 5 Clinical Trial
Official title:
First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System to Evaluate Safety and Performance
Verified date | September 2023 |
Source | PAVmed Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | November 2023 |
Est. primary completion date | November 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 99 Years |
Eligibility | Inclusion Criteria: - Subjects must meet the following criteria are eligible for participation in the study: 1. Subject is > 22 years old 2. Subject has grade 3 or higher CKD and is receiving or may receive renal replacement therapy with hemodialysis OR has poor/difficult vascular access. 3. Subject does NOT need urgent or emergent vascular access; 4. Subject, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated procedures 5. Subject is willing and able to complete follow-up requirement Exclusion Criteria: - Subjects must be EXCLUDED from participation in this study if ANY of the following criteria are met: 1. Fracture (within 6 months), bone tumor, or structural bone abnormality (such as osteogenesis imperfect, avascular necrosis, and severe osteoporosis) of the target bone 2. Excessive overlying soft tissue, nerves, arteries, tendons or absence of anatomic landmarks at the target site 3. Previous orthopedic procedure at or near the insertion site (e.g. artificial joint, rigid fixation hardware) 4. IO access or attempted IO access in the target bone within 7 days 5. Known or suspected allergy to any device component or materials contained in the device 6. Local tissue factors preventing proper device stabilization and / or access including local infection, fragile tissue and absence of adequate or excessive overlying soft tissue. 7. Subject with known unstable cardiac disease (recent MI within 30 days, cardiac surgery within 6 months, unstable angina, severe aortic stenosis/regurgitation, severe congestive heart failure, severe mitral stenosis/regurgitation), uncontrolled diabetes (blood glucose >240 mg/dl) or subjects on immunosuppressive medications (e.g. organ transplant patients) 8. Subjects who are anticipated to receive infusion of blood or blood products, chemotherapeutic agents, hypertonic solutions, caustic agents or any agents known to harm bone marrow or cause bone marrow suppression such as azathioprine, procainamide, sulfasalazine via the test device. 9. Insertion into the humerus on the same side as a previous mastectomy 10. Known allergy to contrast media or local anesthetics (e.g. lidocaine, bupivacaine) 11. Subjects with known bleeding disorders including thrombocytopenia, thrombasthenia, hemophilia or Von Willebrand's disease. 12. Subjects with a history of hypercoagulable disorders such as protein S or C deficiency, Factor 5 Leiden resistance, Antithrombin III deficiency, Antiphospholipid antibody syndrome, Heparin Induced Thrombocytopenia etc. 13. Subjects who are anticipated to need power injections via the test device for CT scan or angiography 14. Subject has other medical, social or psychological problem that in the opinion of the investigator precludes them from fully participating 15. Women who are pregnant, women who are attempting to become pregnant, as well as women who are breast feeding. |
Country | Name | City | State |
---|---|---|---|
Colombia | Cediul | Barranquilla | Atlantico |
Colombia | Sabbag Radiologos | Barranquilla | Atlantico |
Colombia | Cirulaser Andes | Bogotá | Bogota |
Colombia | Centro Medico Imbanaco | Cali | Valle De Cauca |
Lead Sponsor | Collaborator |
---|---|
PAVmed Inc. |
Colombia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Performance | Incidence of successful implant in the target anatomic location; Patency through the implant duration, with final patency assessment performed immediately prior to device explant; Incidence of successful device explant | Entire duration of Study an average of 2 years | |
Primary | Primary Safety | Incidence of serious device-related adverse events | Entire duration of Study and average of 2 years | |
Secondary | Secondary Endpoint | Incidence of all device-related adverse events, whether serious or non-serious | Entire duration of Study an average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
Completed |
NCT05630729 -
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
|
N/A | |
Withdrawn |
NCT03998917 -
Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
|
||
Recruiting |
NCT05489120 -
Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)
|
N/A | |
Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
Recruiting |
NCT01591876 -
Exercise and Vascular Function in Haemodialysis Patients
|
Phase 2 | |
Not yet recruiting |
NCT04608422 -
Bioeletric Stimulation in Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT03868371 -
Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients
|
N/A | |
Active, not recruiting |
NCT05225454 -
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
|
||
Completed |
NCT03459807 -
Blood Pressure Lowering in Dialysis (BOLD) Trial
|
Phase 2 | |
Not yet recruiting |
NCT03005847 -
The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron
|
N/A | |
Recruiting |
NCT05726526 -
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
|
N/A | |
Recruiting |
NCT04330807 -
Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease
|
N/A | |
Active, not recruiting |
NCT02858778 -
Timing of Acute Palliative Care Consultation in Critically Ill Patients
|
N/A | |
Active, not recruiting |
NCT04034966 -
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
|
N/A | |
Completed |
NCT04012957 -
Desidustat in the Treatment of Anemia in CKD
|
Phase 3 | |
Terminated |
NCT02039167 -
Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
|
N/A | |
Completed |
NCT01764854 -
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
|
Phase 2 | |
Active, not recruiting |
NCT05350098 -
Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease
|
N/A |